CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 37 enrolled
Drug / intervention
Methotrexate +4 moredrug
Likely dose
Methotrexate 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00905034
NCT00905034Phase 2Completed
CompareCT.gov

Phase II Study of Methotrexate, Vincristine, Pegylated L-asparaginase and Dexamethasone (MOAD) in Acute Lymphoblastic Leukemia (ALL) Salvage

M.D. Anderson Cancer Center·interventional·Posted May 20, 2009·Updated Jun 29, 2015

In Brief

A Phase 2 clinical trial evaluating Methotrexate, Vincristine, and 3 other interventions for Leukemia, Lymphocytic, Acute. Completed, enrolled 37 participants across 1 site.

Detailed Summary

This goal of this clinical research study is to learn if the combination of methotrexate, pegylated-L-asparaginase, vincristine, and dexamethasone (also rituximab in some patients) can help to control ALL that has not responded to previous treatment or has come back after a response or chronic myeloid leukemia (CML).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, Lymphocytic, Acute
CountriesUnited States
CollaboratorsLeadiant Biosciences, Inc.

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 20, 2009
Enrollment StartMar 1, 2009
Primary CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 17.1 years ago

Interventions

Methotrexatedrug

200 mg/m\^2 by vein on days 1 and 15.

Vincristinedrug

1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.

PEG-l-asparaginasedrug

2500 International units/m\^2 by vein on days 2 and 16

Dexamethasonedrug

40 mg by vein or by mouth daily days 1-4 and 15-18.

Rituximabdrug

Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.